CXCR4^S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635.

Authors

Joshua N Gustine^{1

2}, Lian Xu¹, Nicholas Tsakmaklis¹, Maria G Demos¹, Amanda Kofides¹, Jiaji G Chen¹, Xia Liu¹, Manit Munshi¹, Maria Luisa Guerrera¹, Gloria G Chan¹, Christopher J Patterson¹, Andrew Keezer¹, Kirsten Meid¹, Toni Dubeau¹, Guang Yang^{1

3}, Zachary R Hunter^{1

3}, Steven P Treon^{1

3}, Jorge J Castillo^{1

3}

Affiliations

¹ Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
² Department of Medicine, Boston University School of Medicine, Boston, MA; and.
³ Department of Medicine, Harvard Medical School, Boston, MA.

Abstract

CXCR4^S338X clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib.
CXCR4^S338X clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

Keywords: CXCR4; Lymphomas and Other Lymphoproliferative Conditions; MYD88; NEOPLASIA; Waldenström macroglobulinemia; ibrutinib.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Drug Resistance
Humans
Mutation
Myeloid Differentiation Factor 88 / genetics
Piperidines
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Receptors, CXCR4 / genetics*
Treatment Outcome
Waldenstrom Macroglobulinemia / drug therapy*
Waldenstrom Macroglobulinemia / genetics*
Waldenstrom Macroglobulinemia / pathology

Substances

CXCR4 protein, human
MYD88 protein, human
Myeloid Differentiation Factor 88
Piperidines
Pyrazoles
Pyrimidines
Receptors, CXCR4
ibrutinib
Adenine